Cargando…
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
BACKGROUND: Glioblastoma, the most common malignant primary brain tumor, remains a lethal disease with few therapeutic options. Immunotherapies, particularly immune checkpoint inhibitors (ICPi), have revolutionized cancer treatment, but their role in glioblastoma is uncertain. OBJECTIVE: To review t...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academia Brasileira de Neurologia - ABNEURO
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491432/ https://www.ncbi.nlm.nih.gov/pubmed/35976319 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S129 |